Apatinib, a selective inhibitor of VEGFR-2, is currently undergoing phase II clinical trials for several solid tumors, including hepatocellular carcinoma (NCT04191889) [168], gestational trophoblastic disease (NCT04047017) [169], esophageal squamous cell carcinoma (NCT03603756) [170], and liver cancer (NCT03092895) [171]. Here, KDR is linked to hepatocellular carcinoma.